Phospho-MLKL(S345)抗体—艾普蒂 新品

+ +

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of Phospho-MLKL (S345) expression in (1) L929 treated with Z-VAD + TNF alpha + SM164 cell lysate; (2) Untreated.    

  
  

The Phospho-MLKL(S345) antibody is a critical tool for studying necroptosis, a programmed form of inflammatory cell death. MLKL (Mixed Lineage Kinase Domain-Like) is the terminal executor of necroptosis, activated via phosphorylation by RIPK3 (Receptor-Interacting Protein Kinase 3) in response to stimuli like TNFα, viral infections, or caspase inhibition. Phosphorylation at serine 345 (human) or the analogous serine 346 (mouse) induces MLKL oligomerization and translocation to the plasma membrane, disrupting membrane integrity and causing cell death. This phosphorylation event serves as a key biomarker for necroptosis activation.

The Phospho-MLKL(S345) antibody specifically detects this post-translational modification, enabling researchers to confirm MLKL activation in experimental models. It is widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to study necroptosis in contexts such as inflammatory diseases, neurodegenerative disorders, cancer, and pathogen-host interactions. Validated for use in human, mouse, and rat samples, this antibody helps delineate necroptosis pathways and evaluate therapeutic agents targeting RIPK1/RIPK3/MLKL signaling. Its specificity for the phosphorylated form ensures accurate detection of pathway activation, distinguishing necroptosis from apoptosis or accidental necrosis.